This prospective open-label trial evaluated the use of SBI in individuals with decompensated cirrhosis with ascites. Subjects tolerated the therapy well, with all nine individuals completing the trial without significant adverse events or changes to any of the quality of life domains that we examined. Similarly, there were no concerns for progressive liver dysfunction in this group, as there were no significant changes in liver enzymes, bilirubin, albumin, sodium, and international normalized ratio when comparing individuals before and after treatment. This evidence concerns the gene ALB and Ascites.